Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   3:59:58 PM EDT
692.92
+9.48 (+1.39%)
Other Pre-Announcement

Regeneron Reports First Quarter 2022 Financial

Published: 05/04/2022 10:42 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - Regeneron Reports First Quarter 2022 Financial and Operating Results.
Q1 Non-GAAP Earnings per Share $11.49.
Q1 GAAP Earnings per Share $8.61.
Q1 2022 Revenues Increased 17% to $2.97 Billion Versus Q1 2021.
Q1 2022 Dupixent Global Net Sales(recorded by Sanofi) Increased 43% to $1.81 Billion Versus Q1 2021.
Q1 2022 Eylea U.S. Net Sales Increased 13% to $1.52 Billion Versus Q1 2021.
Has Approximately 35 Product Candidates in Clinical Development.
Q1 Earnings per Share View $9.89, Revenue View $2.72 Billion -- Refinitiv Ibes Data (analyst estimates).
Sees FY Capital Expenditures $630 Million-$700 Million.
Regeneron Pharmaceuticals - Progressing Investigational "next Generation" Antibodies That Are Active Against Multiple Variants Including Those of Omicron-lineage.